Targeting PSMA for Prostate Cancer Diagnosis and Treatment
PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy
This project explores a new way to find and treat advanced prostate cancer by focusing on a specific protein called PSMA.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11114031 on NIH RePORTER |
What this research studies
Many prostate cancer patients initially respond to hormone therapy, but their cancer often becomes resistant and progresses to a more aggressive form that is very difficult to treat. Our team has uncovered a new function of a protein called PSMA, which is found at high levels in aggressive prostate cancer and helps the cancer grow. This research aims to stop prostate cancer growth by blocking this newly discovered activity of PSMA. We hope to develop a completely new, personalized treatment strategy that is different from current therapies. Additionally, we are working on a new imaging method to better diagnose and monitor prostate cancer.
Who could benefit from this research
Good fit: Patients with aggressive prostate cancer, particularly those whose cancer has become resistant to hormone therapy, might be ideal candidates for future applications of this research.
Not a fit: Patients with early-stage prostate cancer that responds well to existing hormone therapies may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this could offer a new, personalized treatment option and improved diagnostic tools for patients with advanced prostate cancer that has become resistant to standard hormone therapy.
How similar studies have performed: This approach is based on a newly discovered biological function of PSMA, making it a novel strategy for prostate cancer treatment.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Grimm, Jan — Sloan-Kettering Inst Can Research
- Study coordinator: Grimm, Jan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.